Assembly biosciences and door pharmaceuticals sign collaboration and option agreement to develop a novel class of hbv core protein modulators

South san francisco, calif., nov. 16, 2020 (globe newswire) -- assembly biosciences, inc. (nasdaq: asmb) and door pharmaceuticals, llc today announced that the companies have signed an exclusive, two-year collaboration and option agreement focused on the development of a novel class of hepatitis b virus (hbv) core protein modulators. door pharmaceuticals' innovative discovery platform targets functions of core protein distinct from viral assembly and that have the potential to interfere with viral nucleic acid including cccdna transcription, providing a strong complement to assembly bio's current portfolio.
ASMB Ratings Summary
ASMB Quant Ranking